摘要:
This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.
摘要:
Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.
摘要翻译:公开了式1化合物,其中V是CH 2; W为S(O)m; m是整数0,1或2; U是O,C(O),CR 13 R 14或NR 15; 其中R 13为H,烷基; R14是H,OH,OR13或OCOR13; R 15是H,烷基,环烷基,烯基,C(O)R 13,C(O)OR 13或烷基氨基羰基; R1,R2,R3,R4,R5,R6,R7和R8如本文所定义。 这些化合物是肿瘤坏死因子-α(TNF-α)的抑制剂,可用作治疗和预防由增加的TNF-α活性引起的疾病,特别是炎症的药物。
摘要:
Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R5 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.
摘要翻译:公开了式1化合物,其中V是CH 2; W为S(O)m; m是整数0,1或2; U是O,C(O),CR 13 R 14或NR 15; 其中R 13为H,烷基; R14是H,OH,OR13或OCOR13; R 15是H,烷基,环烷基,烯基,C(O)R 13,C(O)OR 13或烷基氨基羰基; R1,R2,R3,R4,R5,R6,R7和R5如本文所定义。 这些化合物是肿瘤坏死因子-α(TNF-α)的抑制剂,可用作治疗和预防由增加的TNF-α活性引起的疾病,特别是炎症的药物。
摘要:
Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.
摘要翻译:公开了式1的化合物,其中V是CH 2 2; W是S(O)m。 m是整数0,1或2; U是O,C(O),CR 13 R 14或NR 15; 其中R 13是H,烷基; R 14是H,OH,OR 13或OCOR 13; R 15是H,烷基,环烷基,烯基,C(O)R 13,C(O)OR 13或烷基氨基羰基; R 1,R 2,R 3,R 4,R 5, R 6,R 7和R 8是如本文所定义的。 这些化合物是肿瘤坏死因子-α(TNF-α)的抑制剂,可用作治疗和预防由增加的TNF-α活性引起的疾病,特别是炎症的药物。
摘要:
Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.
摘要翻译:公开了式1化合物,其中V是CH 2; W为S(O)m; m是整数0,1或2; U是O,C(O),CR 13 R 14或NR 15; 其中R 13为H,烷基; R14是H,OH,OR13或OCOR13; R 15是H,烷基,环烷基,烯基,C(O)R 13,C(O)OR 13或烷基氨基羰基; R1,R2,R3,R4,R5,R6,R7和R8如本文所定义。 这些化合物是肿瘤坏死因子-α(TNF-α)的抑制剂,可用作治疗和预防由增加的TNF-α活性引起的疾病,特别是炎症的药物。
摘要:
Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.
摘要翻译:公开了式1化合物,其中V是CH 2; W为S(O)m; m是整数0,1或2; U是O,C(O),CR 13 R 14或NR 15; 其中R 13为H,烷基; R14是H,OH,OR13或OCOR13; R 15是H,烷基,环烷基,烯基,C(O)R 13,C(O)OR 13或烷基氨基羰基; R1,R2,R3,R4,R5,R6,R7和R8如本文所定义。 这些化合物是肿瘤坏死因子-α(TNF-α)的抑制剂,可用作治疗和预防由增加的TNF-α活性引起的疾病,特别是炎症的药物。